Erectile Dysfunction Following Radical ProstatectomyNCT06200987
Penile Vibratory Stimulation in the Prevention of Sexual Dysfunction and Urinary Incontinence After Radical Prostatectomy
A study testing Penile vibrator in people with Erectile Dysfunction Following Radical Prostatectomy and Incontinence, run by Herlev and Gentofte Hospital at 1 site in Denmark.
Trial summary
To investigate if post-operative penile vibration stimulation kan be used to reduce or prevent sexual dysfunction and urinary incontinence after radical prostatectomy. This will be done in a randomized, controlled, non-blinded study. Read more about this study
- Who is it for?
- Ages 18 years and older, men only
- Conditions the study is for
- Erectile Dysfunction Following Radical Prostatectomy, Incontinence
- What is being tested?
- Penile vibrator
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- 1 siteDenmark
- Study dates
- 1 Feb 2024to Oct 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Men only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Men who are undergoing nerve-sparing radical prostatectomy
- Pre operative erectile function of IIEF-EF > 25
- Sexually active . Continent before surgery defined as a score of 0 on the ICIQ-SF questionnaire
Who cannot join
- Urinary incontinent before surgery
- Comorbidity that prevents the patient from taking PDE5-inhibitors
- Disease in the penis or in the penile skin (Peyronies, phimosis)
- Problems using the vibrator ie impaired function of the hands
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Denmark1 site, 1 recruiting
- Recruiting
Herlev and Gentofte Hospital
Herlev, 2730
Mette LK Schmidt, PHD, +4538681100, Mette.Ladefoged.Kopp.Schmidt@regionh.dk
About this study
Official title: Planned Penile Vibratory Stimulation in the Prevention of Sexual Dysfunction and Urinary Incontinence After Radical Prostatectomy: a Randomized Controlled Study
To investigate if post-operative penile vibration stimulation kan be used to reduce or prevent sexual dysfunction and urinary incontinence after radical prostatectomy. This will be done in a randomized, controlled, non-blinded study. Men that undergo nerve preserving surgery for prostate cancer is allocated into an intervention group and a control group. A total of 100 men will be included for a power of 80%. The intervention group will be instructed to use the "Ferticare 2.0" vibrator for at least five minutes a day with an amplitude of 1 mm and frequency of 90 Hz (these settings were found in a pilot study) for a total of 9 months.
Both groups will do the standard pelvic floor training program and both groups will be offered regular phosphodiesterase-5-inhibitor treatment. Before surgery, 3, 6 and 10 months after the patients will have to fill out four different questionnaires regarding sexual and urinary function, including IIEF-EF, EHS, "neglected side effects" and ICIQ-SF. (10 months is due to a wash-out period of 1 month after the intervention).
The collected data will be analysed and the primary goal is to see if there is a significant difference in average spontaneous IIEF-EF score in the two groups 10 months after the surgery.
Read the detailed description
Hypothesis The study's hypothesis is that vibration therapy, using the stimulation parameters found in the pilot study, will have a beneficial effect on erectile function, orgasm disturbances, penile shortening, and urinary incontinence, both generally and in connection with sexual activity.
Methods The study is conducted as a randomized, controlled non-blinded study. Men undergoing a nerve-sparing operation for prostate cancer are divided into two groups. A total of 100 men will be included in the study. In case a surgery cannot be performed with nerve preservation or if a participant experiences a recurrence of their prostate cancer requiring additional treatment, the participant will be withdrawn from the study.
Randomization and Treatment Overall, we will investigate the effect of vibration stimulation on erectile function, orgasm disturbances, penile shortening, and urinary incontinence, both generally and in connection with sexual activity. In accordance with the hypotheses, this study will offer vibration therapy for a longer duration than before. Both the vibration group and the control group will be offered fixed post-operative treatment with phosphodiesterase-5-inhibitors as per the standard protocol. Participants will be randomized into the two groups through drawing lots for either vibration or no vibration. Randomization will be done using block randomization via a computer-generated list. The "Ferticare 2.0" vibrator (produced by the company Reflexonic LLC, Leesburg VA, USA) will be used in the study, which is a modernized version of the previously used vibrator and is sold as a sexual aid in Denmark. It is safety-approved with European CE marking as a "household appliance" and is sold as a sexual aid in Denmark. Men in the vibration group will be instructed on the stimulation before their prostate surgery. Subsequently, participants will be able to perform the vibration therapy themselves at home. In both groups, participants must undergo a standard pelvic floor training program, and both groups will be offered fixed PDE-5 inhibitor treatment in the form of daily tadalafil, 5 mg, as the standard treatment for erectile difficulties after the operation. In the vibration group, daily stimulation will be directed towards the frenulum for a minimum of 5 minutes, with an amplitude of 1 mm and a frequency of 90 Hz, as found in the pilot study. Participants will start getting used to the vibration 1-4 weeks before the surgery and resume it within 14 days after the operation. The daily stimulation will continue for a period of 9 months, along with the standard treatment. After these 9 months, men in both groups will stop taking tadalafil during a 4-week wash-out period, after which their spontaneous sexual function will be evaluated. This is necessary due to the well-known positive effect of the medication. In comparison to the standard treatment in the department, offering vibration to half of the participants is an addition. Regarding pelvic floor training and medication for erectile difficulties for all study participants, the current standard is to offer these to all men who have undergone nerve-sparing radical prostatectomy. This will proceed as usual, and the only deviation from usual practice is ensuring that the medication offer is consistent for all participants. The mentioned 4-week period without tablet treatment (wash-out) is necessary to assess spontaneous erections. This is a deviation from the normal standard, as such a wash-out is not conducted for patients who do not participate in research, but it will not affect the actual erectile function of the participants in either group.
Data Collection
Standard investigations related to prostate cancer will be conducted according to normal guidelines, with the registration of:
- Pre-operative PSA
- Clinical and pathological tumor stage
- Gleason score
- Prostate size
- Degree of nerve preservation during the surgery
- Any complications during the surgery
- Resection margin status (positive or negative)
- PSA measurements at 3, 6, and 12 months after the operation. This information will be obtained from the patient's medical records by the scientific staff after the study participants have given their consent to participate. After providing consent, the study organizers, sponsor, sponsor's representatives, and any regulatory authorities will have direct access to obtain information from the patient's medical records, including electronic records, for the purpose of reviewing information about the research participant's health, as necessary for conducting the research project and for monitoring, including self-monitoring, quality control, and oversight, as they are obligated to perform.
Since potential participants are screened and informed about the project during their visits to the outpatient clinic (see the section on Recruitment of Study Participants and Informed Consent), there is no need to obtain information from the patient's medical records before consent is given. At this stage, the research team only receives the name, social security number, and contact information for patients who have expressed interest in the project.
Additional examinations are carried out before the surgery and at follow-ups at 3 months, 6 months, and 10 months (equivalent to the end of the wash-out period) after the surgery, with the registration of the following for all participants in both the vibration group and the control group:
Before the surgery and at follow-ups:
- Validated symptom questionnaires for erectile function (IIEF-EF and EHS)
- Specific questionnaire about orgasm disturbances, penile shortening, and urinary incontinence during sexual activity.
- Validated symptom questionnaire for incontinence symptoms (ICIQ-SF)
- 24-hour pad weighing test (only at follow-ups for men who are not fully continent)
Additional registrations at follow-ups:
- Registration of PSA recurrence after the surgery and noting any additional treatment
- Any side effects of vibration and standard treatment
- Being tested
- Penile vibrator
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Penile vibratorDevice
In addition to standard treatment with PDE5-inhibitors the intervention is daily stimulation for five minutes with the vibrator for 9 months
| Study group | Role | What they receive |
|---|---|---|
| Intervention | Experimental | The group randomized to use the vibrator for 9 months Receives: Device: Penile vibrator |
| Controls | No intervention | Usual standard treatment |
What is being measured
The primary outcome is the main question the study is designed to answer.
Erectile function
The erectile function compared to controls measured by IIEF-EF
Measured: 10 months
Secondary outcomes (6)
ICIQ-UI-SF: The International Consultation on Incontinence Questionnaire - Urinary Incontinence - short form
Difference in ICIQ-SF score between the two groups after 3, 6 and 10 months. The score is from 0-21. The higher the score the more incontinent. A score of 0 is no urinary incontinence.
Measured: 10 months
IIEF-EF score (The International Index of Erectile Function - Erectile Function)
Difference in IIEF-EF score between the two groups after 3, 6 and 10 months. The minimum score is 0 and the maximum score is 30. The higher the score the better erectile function.
Measured: 10 months
Diaper weighing test
Difference in 24 hour diaper weighing test between the two groups after 3, 6 and 10 months
Measured: 10 months
IIEF-EF (The International Index of Erectile Function - Erectile Function) over 25
The percentage of patients who gain a post-operative spontaneous IIEF-EF score of at least 25. The minimum score is 0 and the maximum score is 30. The higher the score the better erectile function.
Measured: 10 months
EHS (Erection Hardness Scale)
The percentage of patients who gain a post-operative spontaneous EHS of at least 3. The scale is from 0-4. 0 is no erection, the higher the score the better erection.
Measured: 10 months
Neglected sexual side effects
The presence of orgasm disturbances, penile shortening and urinary incontinence in relation to sexual activity.
Measured: 10 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Jan 2024
- Study start1 Feb 2024
- Primary completionMar 2026 (estimated)
- Study completionOct 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Erectile Dysfunction Following Radical ProstatectomyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Herlev and Gentofte Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Helene Reif Andersen, Herlev and Gentofte Hospital
- Investigators
- Mikkel Fode, MD, PhD, Principal investigator, Department of Urology, Herlev and Gentofte University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06200987
- Sponsor's protocol ID
- ProVibrate
- Status last verified
- Mar 2024
- First submitted
- 29 Dec 2023
- Last updated
- 12 Mar 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- Yes: Available upon request. Subject to approval from the Danish Data Protection Agency.
Study at a glance
From the registry record, last updated by the sponsor on 12 Mar 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Planned Penile Vibratory Stimulation in the Prevention of Sexual Dysfunction and Urinary Incontinence After Radical Prostatectomy: a Randomized Controlled Study
- ClinicalTrials.gov ID
- NCT06200987
- Acronym / sponsor ID
- ProVibrate
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Herlev and Gentofte HospitalUniversity, hospital or other
- Study start
- 1 Feb 2024 (actual)
- Primary completion
- Mar 2026 (estimated)
- Study completion
- Oct 2026 (estimated)
- First posted
- 11 Jan 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To investigate if post-operative penile vibration stimulation kan be used to reduce or prevent sexual dysfunction and urinary incontinence after radical prostatectomy. This will be done in a randomized, controlled, non-blinded study. Men that undergo nerve preserving surgery for prostate cancer is allocated into an intervention group and a control group. A total of 100 men will be included for a power of 80%. The intervention group will be instructed to use the "Ferticare 2.0" vibrator for at least five minutes a day with an amplitude of 1 mm and frequency of 90 Hz (these settings were found in a pilot study) for a total of 9 months.
Both groups will do the standard pelvic floor training program and both groups will be offered regular phosphodiesterase-5-inhibitor treatment. Before surgery, 3, 6 and 10 months after the patients will have to fill out four different questionnaires regarding sexual and urinary function, including IIEF-EF, EHS, "neglected side effects" and ICIQ-SF. (10 months is due to a wash-out period of 1 month after the intervention).
The collected data will be analysed and the primary goal is to see if there is a significant difference in average spontaneous IIEF-EF score in the two groups 10 months after the surgery.
Detailed description
Hypothesis The study's hypothesis is that vibration therapy, using the stimulation parameters found in the pilot study, will have a beneficial effect on erectile function, orgasm disturbances, penile shortening, and urinary incontinence, both generally and in connection with sexual activity.
Methods The study is conducted as a randomized, controlled non-blinded study. Men undergoing a nerve-sparing operation for prostate cancer are divided into two groups. A total of 100 men will be included in the study. In case a surgery cannot be performed with nerve preservation or if a participant experiences a recurrence of their prostate cancer requiring additional treatment, the participant will be withdrawn from the study.
Randomization and Treatment Overall, we will investigate the effect of vibration stimulation on erectile function, orgasm disturbances, penile shortening, and urinary incontinence, both generally and in connection with sexual activity. In accordance with the hypotheses, this study will offer vibration therapy for a longer duration than before. Both the vibration group and the control group will be offered fixed post-operative treatment with phosphodiesterase-5-inhibitors as per the standard protocol. Participants will be randomized into the two groups through drawing lots for either vibration or no vibration. Randomization will be done using block randomization via a computer-generated list. The "Ferticare 2.0" vibrator (produced by the company Reflexonic LLC, Leesburg VA, USA) will be used in the study, which is a modernized version of the previously used vibrator and is sold as a sexual aid in Denmark. It is safety-approved with European CE marking as a "household appliance" and is sold as a sexual aid in Denmark. Men in the vibration group will be instructed on the stimulation before their prostate surgery. Subsequently, participants will be able to perform the vibration therapy themselves at home. In both groups, participants must undergo a standard pelvic floor training program, and both groups will be offered fixed PDE-5 inhibitor treatment in the form of daily tadalafil, 5 mg, as the standard treatment for erectile difficulties after the operation. In the vibration group, daily stimulation will be directed towards the frenulum for a minimum of 5 minutes, with an amplitude of 1 mm and a frequency of 90 Hz, as found in the pilot study. Participants will start getting used to the vibration 1-4 weeks before the surgery and resume it within 14 days after the operation. The daily stimulation will continue for a period of 9 months, along with the standard treatment. After these 9 months, men in both groups will stop taking tadalafil during a 4-week wash-out period, after which their spontaneous sexual function will be evaluated. This is necessary due to the well-known positive effect of the medication. In comparison to the standard treatment in the department, offering vibration to half of the participants is an addition. Regarding pelvic floor training and medication for erectile difficulties for all study participants, the current standard is to offer these to all men who have undergone nerve-sparing radical prostatectomy. This will proceed as usual, and the only deviation from usual practice is ensuring that the medication offer is consistent for all participants. The mentioned 4-week period without tablet treatment (wash-out) is necessary to assess spontaneous erections. This is a deviation from the normal standard, as such a wash-out is not conducted for patients who do not participate in research, but it will not affect the actual erectile function of the participants in either group.
Data Collection
Standard investigations related to prostate cancer will be conducted according to normal guidelines, with the registration of:
- Pre-operative PSA
- Clinical and pathological tumor stage
- Gleason score
- Prostate size
- Degree of nerve preservation during the surgery
- Any complications during the surgery
- Resection margin status (positive or negative)
- PSA measurements at 3, 6, and 12 months after the operation. This information will be obtained from the patient's medical records by the scientific staff after the study participants have given their consent to participate. After providing consent, the study organizers, sponsor, sponsor's representatives, and any regulatory authorities will have direct access to obtain information from the patient's medical records, including electronic records, for the purpose of reviewing information about the research participant's health, as necessary for conducting the research project and for monitoring, including self-monitoring, quality control, and oversight, as they are obligated to perform.
Since potential participants are screened and informed about the project during their visits to the outpatient clinic (see the section on Recruitment of Study Participants and Informed Consent), there is no need to obtain information from the patient's medical records before consent is given. At this stage, the research team only receives the name, social security number, and contact information for patients who have expressed interest in the project.
Additional examinations are carried out before the surgery and at follow-ups at 3 months, 6 months, and 10 months (equivalent to the end of the wash-out period) after the surgery, with the registration of the following for all participants in both the vibration group and the control group:
Before the surgery and at follow-ups:
- Validated symptom questionnaires for erectile function (IIEF-EF and EHS)
- Specific questionnaire about orgasm disturbances, penile shortening, and urinary incontinence during sexual activity.
- Validated symptom questionnaire for incontinence symptoms (ICIQ-SF)
- 24-hour pad weighing test (only at follow-ups for men who are not fully continent)
Additional registrations at follow-ups:
- Registration of PSA recurrence after the surgery and noting any additional treatment
- Any side effects of vibration and standard treatment
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Intervention | Experimental | Device: Penile vibratorThe group randomized to use the vibrator for 9 months |
| Controls | No intervention | –Usual standard treatment |
Who may qualify
- Ages
- 18 years and older
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Men who are undergoing nerve-sparing radical prostatectomy
- Pre operative erectile function of IIEF-EF > 25
- Sexually active . Continent before surgery defined as a score of 0 on the ICIQ-SF questionnaire
Key exclusion criteria (4 listed)
- Urinary incontinent before surgery
- Comorbidity that prevents the patient from taking PDE5-inhibitors
- Disease in the penis or in the penile skin (Peyronies, phimosis)
- Problems using the vibrator ie impaired function of the hands
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Penile vibratorIn addition to standard treatment with PDE5-inhibitors the intervention is daily stimulation for five minutes with the vibrator for 9 months | Device | Intervention |
Primary outcome
Erectile function
Time frame: 10 months
The erectile function compared to controls measured by IIEF-EF
6 secondary outcomes
ICIQ-UI-SF: The International Consultation on Incontinence Questionnaire - Urinary Incontinence - short form
Time frame: 10 months
IIEF-EF score (The International Index of Erectile Function - Erectile Function)
Time frame: 10 months
Diaper weighing test
Time frame: 10 months
IIEF-EF (The International Index of Erectile Function - Erectile Function) over 25
Time frame: 10 months
EHS (Erection Hardness Scale)
Time frame: 10 months
Neglected sexual side effects
Time frame: 10 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Mar 2024.
- Individual participant dataSharing planned: Yes. Available upon request. Subject to approval from the Danish Data Protection Agency.
Related trials for Erectile Dysfunction Following Radical Prostatectomy
RecruitingPhase 2
Multimodal Prehabilitation and Rehabilitation for Men Undergoing Robot-Assisted Radical Prostatectomy
Erectile Dysfunction Following Radical Prostatectomy, Prostate Cancer
Not yet recruiting
Platelet-Rich Plasma for Erectile Dysfunction After Radical Prostatectomy: a Randomized Controlled Trial
Erectile Dysfunction Following Radical Prostatectomy, Erectile Dysfunction
Recruiting
Tractography-Guided Nerve-Sparing in Prostate Cancer
Prostate Cancer, Erectile Dysfunction Following Radical Prostatectomy
Active, not recruiting
Safety and Tolerability of a Novel Implantable Device for the Treatment of Erectile Dysfunction
Erectile Dysfunction Following Radical Prostatectomy
Recruiting
Efficacy of RestoreX Penile Traction Therapy In Preserving Erectile Function Post-Prostatectomy
Erectile Dysfunction Following Radical Prostatectomy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Mikkel Fode, MD, PhD principal investigator
Department of Urology, Herlev and Gentofte University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Penile vibrator in people with Erectile Dysfunction Following Radical Prostatectomy and Incontinence, run by Herlev and Gentofte Hospital at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 12 Mar 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Helene R Andersen, MD (+4538681507, helene.reif.andersen@regionh.dk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Erectile function (time frame: 10 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Mar 2024; AzTrials last refreshed its copy on 26 Oct 2026.